neurology

News

Teva makes its first M&A play in years, buying Emalex

Teva has made its first pipeline-building acquisition in almost a decade, buying Tourette syndrome drug developer Emalex for up to $900m.

News

New data build case for Roche's oral BTK drug for MS

Roche remains confident in the prospects for its soon-to-be-filed oral BTK drug fenebrutinib for multiple sclerosis, despite safety concerns.

News

UCB cuts $1.15bn deal to buy epilepsy biotech Neurona

UCB has dipped its toe into the M&A waters once again with an agreement to buy US biotech Neurona and its cell therapy for a common form of epilepsy.

R&D

Neuroplasticity modulators as innovative potential disease-m...

In September last year, we reported Servier had advanced its emerging neurology pipeline into the clinical trials stage by licensing a drug for the rare genetic disorder Fragile X syndrome

News

Most patients "won't see benefit" with Alzheimer's drugs

A review of clinical data on amyloid-targeting Alzheimer's therapies has found absent or trivial efficacy, but is facing pushback from some experts.

R&D

Female neuroscientist surveys brain scans

From genetic insight to Phase 3: What rare neurology require...

Rare neurology is not defined by a lack of scientific opportunity or capital.

Teva makes its first M&A play in years, buying Emalex

New data build case for Roche's oral BTK drug for MS

UCB cuts $1.15bn deal to buy epilepsy biotech Neurona

Neuroplasticity modulators as innovative potential disease-m...

Most patients "won't see benefit" with Alzheimer's drugs

From genetic insight to Phase 3: What rare neurology require...

Parexel buys Vitrana to boost patient safety toolkit

Discover a new era of healthcare panel engagement: Grounded ...

neurology

Editor's Picks